AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

CRANEWARE PLC

Remuneration Information Mar 26, 2020

7581_dirs_2020-03-26_b70b3f7f-9300-4afb-9417-ad57c75c848d.html

Remuneration Information

Open in Viewer

Opens in native device viewer

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 7713H

Craneware plc

26 March 2020

Craneware plc

("Craneware" or the "Company")

Vesting of Long Term Incentive Plan Award

26 March 2020 - The Board of Craneware plc (AIM: CRW.L), the market leader in Value Cycle solutions for the US healthcare market, announces that on 24 March 2020, under the terms of the Craneware plc Long Term Incentive Plan (2016) ("LTIP"), a conditional award of ordinary shares of 1p each in the Company ("Shares") which was granted to a Director of the Company on 24 March 2017, vested following the satisfaction of certain performance conditions.  

Craig Preston, a Director and CFO of the Company, received a net amount of 3,824 Shares, which is 0.01% of the issued share capital of the Company, from the vested LTIP award after deduction of the associated tax liabilities. No consideration was payable by Craig Preston to receive the Shares from this LTIP award.

Following this transaction, Craig Preston holds 85,927 Shares which is 0.32% of the issued share capital of the Company.  

PDMR notification: Craig Preston

1.   Details of the Restricted Person / person closely associated with him or her

a) Name                                                            Craig Preston

2.   Reason for the notification

a) Position / status                                            CFO

b) Initial notification / Amendment                       Initial notification

3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name                                                            Craneware plc

b) LEI                                                                213800O2CTJ1YFXNXG05

4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a) Description of the financial instrument, type of

instrument                                                         Ordinary shares of 1p each in the capital of Craneware plc

b) Identification code                                         ISIN GB00B2425G68

c) Nature of the transaction                                Vesting of conditional share award under the Craneware plc

Long Term Incentive Plan (2016)

d) Price(s) and volume(s)                                   Volume(s) released from vested award 3,824, Price(s) £0

e) Aggregated information:

i. Aggregated volume                Aggregate volume released 3,824

ii. Price                                     Price(s) £0

f) Date of the transaction                                  2020-03-24

g) Place of the transaction                                 Outside a trading venue

For further information, please contact:

Craneware plc Peel Hunt (NOMAD & Joint Broker) Investec Bank (Joint Broker) Alma (Financial PR)
+44 (0)131 550 3100 +44 (0)20 7418 8900 +44 (0)20 7597 5970 +44 (0)203 405 0205
Keith Neilson, CEO Dan Webster Patrick Robb Caroline Forde
Craig Preston, CFO George Sellar

Andrew Clark
Sebastian Lawrence

Henry Reast
Hilary Buchanan

Helena Bogle

About Craneware

Craneware (AIM: CRW.L), the leader in automated value cycle solutions, collaborates with U.S. healthcare providers to plan, execute and monitor value-based economic performance. Founded in 1999, Craneware is headquartered in Edinburgh, Scotland with offices in Atlanta and Pittsburgh employing over 350 staff. Craneware's value cycle management suite includes charge capture, strategic pricing, patient engagement, claims analytics, revenue recovery and retention, and cost and margin intelligence solutions.

Learn more at www.craneware.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

END

DSHFLFFRVTIRFII

Talk to a Data Expert

Have a question? We'll get back to you promptly.